This study evaluates MT use in first-line therapy decisions and its impact on treatment for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Methods: This retrospective study analyzed genomic data from July 2018 to December 2023, sourced from NeoGenomics Laboratories and linked with Symphony administrative claims data.
Categories